NCT00485485View on ClinicalTrials.gov

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Head and Neck CancerSquamous Cell Cancer

Interventions

DRUG

Imatinib Mesylate

400 mg by mouth daily

DRUG

Docetaxel

60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER